View Older Stories View More Recent Stories
-
Inspire Medical Systems (INSP) Spikes on Keybanc Comments, 'CMS Appears Ready to Add INSP V Specific C-Codes in April 2026 IOCE Update'
-
Inspire Medical Systems (INSP) Strength Tied to CMS Code
-
Wolfe downgrades Inspire Medical on Medicare payment reversal
-
Wolfe Research Downgrades Inspire Medical Systems (INSP) to Peerperform
-
Inspire Medical Systems (INSP) PT Lowered to $95 at Stifel
-
Inspire Medical Systems (INSP) PT Lowered to $70 at Truist Securities
-
Inspire Medical Systems (INSP) PT Lowered at RBC Capital Amid 2026 Guidance Cut
-
Inspire Medical Systems (INSP) PT Lowered to $85 from $165 at Piper Sandler
-
Nephron Downgrades Inspire Medical Systems (INSP) to Hold
-
Wells Fargo Downgrades Inspire Medical Systems (INSP) to Equal Weight
-
Baird Downgrades Inspire Medical Systems (INSP) to Neutral
-
Inspire Medical Systems (INSP) Tops Q4 EPS by 97c
-
RBC Capital Downgrades Inspire Medical Systems (INSP) to Sector Perform
-
KeyBanc on Medical Technology: 'From Reset to Rebound?'
-
Inspire Medical Systems (INSP) PT Lowered to $81 at Jefferies
-
Truist Securities Downgrades Inspire Medical Systems (INSP) to Hold
-
Evercore ISI Reiterates Outperform Rating on Inspire Medical Systems (INSP)
-
Oppenheimer Downgrades Inspire Medical Systems (INSP) to Perform
-
Inspire Medical Systems (INSP) PT Raised to $100 at Jefferies
-
Inspire Medical Systems reports preliminary Q4 2025 revenue of $269 million
-
Inspire Medical Systems (INSP) PT Lowered to $120 at Truist Securities
-
Oppenheimer on Inspire Medical Systems (INSP): 'Uncertainty Rising'
-
Stifel weighs in on Inspire Medical Systems (INSP) weakness
-
Inspire Medical Systems (INSP) PT Raised as Piper Sandler Sees 'More Room For The Stock To Run'
-
Oppenheimer Upgrades Inspire Medical Systems (INSP) to Outperform
-
Truist Securities Upgrades Inspire Medical Systems (INSP) to Buy
-
Wolfe Research Upgrades Inspire Medical Systems (INSP) to Outperform, PT $180
-
Inspire Medical Systems (INSP) PT Raised to $128 at Truist Securities
-
UBS Reiterates Neutral Rating on Inspire Medical Systems (INSP)
-
Nephron Upgrades Inspire Medical Systems (INSP) to Buy
-
Stifel Upgrades Inspire Medical Systems (INSP) to Buy
-
Attention Long-Term Shareholders of Inspire Medical Systems, Inc. (INSP): Grabar Law Office is Investigating Claims on Your Behalf
-
Important Notice to Long-Term Shareholders of Inspire Medical Systems, Inc. (INSP): Grabar Law Office Is Investigating Claims on Your Behalf
-
Inspire Medical Systems (INSP) PT Lowered to $125 at RBC Capital
-
Inspire Medical Systems (INSP) PT Lowered to $135 at Piper Sandler
-
Inspire Medical Systems (INSP) PT Lowered to $110 at Mizuho
-
KeyBanc on Inspire Medical Systems (INSP): '3Q25 Demonstrating Incremental Stability'
-
Wells Fargo Upgrades Inspire Medical Systems (INSP) to Overweight
-
Inspire Medical Systems (INSP) Tops Q3 EPS by 58c, provides guidance
-
Jefferies Downgrades Inspire Medical Systems (INSP) to Hold
-
Inspire Medical Systems presents clinical data for new sleep apnea device
-
Inspire Medical Systems (INSP) call put ratio 2.1 calls to 1 put as share price down 1.1%
-
UBS Downgrades Inspire Medical Systems (INSP) to Neutral as Shares Fall 40pct Since Last Note
-
Evercore ISI Starts Inspire Medical Systems (INSP) at Outperform
-
KeyBanc Reiterates SW Rating on Inspire Medical Systems (INSP) Amid CFO Transition
-
Inspire Medical Systems (INSP) PT Lowered to $97 at Leerink Partners
-
Inspire Medical Systems ALERT: Securities Fraud Investigation by Block & Leviton Could Allow INSP Investors to Recover Losses
-
Inspire Medical Systems (INSP) 6400 contracts trade, compared to its 90-day average of 110 contracts as share price down 37%
-
Inspire Medical Systems (INSP) PT Lowered at RBC Capital Amid a 'Notable Guidance Reduction'
-
Inspire Medical Systems (INSP) PT Slashed at Piper Sandler After a Large Guidance Cut
